A clinical study found that the elimination half-lives of darolutamide and ketodarolutamide at steady-state were 15.8 hours and 10.0 hours, respectively, with these half-lives being independent of dosage across a dose range of darolutamide of 200 to 1,800 mg/day. The elimination half-life of darolutamide is far shorter than that of enzalutamide (e.g., 1.6 hours vs. 18.3 hours in mice). The clearance of darolutamide following intravenous administration is 116 mL/min. Excretion
After a single oral dose of darolutamide, more than 95% of the dose is excreted in urine and feces within one week following administration. A total of 63.4% darolutamide-related material is recovered in urine (about 7% as unchanged darolutamide) and a total of 32.4% darolutamide-related material (about 30% as unchanged darolutamide) is recovered in feces. Variability
No clinically significant differences in the pharmacokinetics of darolutamide have been observed in men with nmCRPC on the basis of age (48 to 95 years), race (white, Asian, black), mild-to-moderate renal impairment, or mild hepatic impairment. In non-nmCRPC individuals with severe renal impairment not on dialysis, exposure to darolutamide was increased by about 2.5-fold relative to healthy people. In non-nmCRPC individuals with moderate hepatic impairment, darolutamide exposure was increased by about 1.9-fold compared to healthy controls. The pharmacokinetics of darolutamide have not been assessed in end-stage kidney disease or severe hepatic impairment. Chemistry
Darolutamide is a nonsteroidal compound and is structurally distinct from other marketed NSAAs, including enzalutamide and apalutamide. History
Darolutamide was developed by Orion Corporation and Bayer HealthCare.
Tinea faciei is a fungal infection of the skin of the face. It generally appears as a photosensitive painless red rash with small bumps and a raised edge appearing to grow outwards, usually over eyebrows or one side of the face. It may feel wet or have some crusting, and overlying hairs may fall out easily. There may be a mild itch. Treatment
Most infections can be treated with topical antifungal medication. Rarely, more extensive or long-standing infections may require treatment with oral antifungals. The infection will still be contagious between 24 and 48 hours of the first treatment. The ringworm should go away within 4–6 weeks after using effective treatment. See also
Tinea corporis
Antifungal drug
List of cutaneous conditions

References


== External links ==